女性泌尿生殖器疾病和妊娠并發(fā)癥
女性泌尿生殖器疾病和妊娠并發(fā)癥是影響女性健康的重要問題。這些疾病包括但不限于尿路感染、陰道炎、子宮內(nèi)膜異位癥、子宮肌瘤、妊娠期糖尿病、妊娠高血壓等。
- 女性泌尿生殖器疾病中,尿路感染和陰道炎較為常見,這些疾病通常由細菌、真菌或病毒引起。治療這些疾病的藥物主要包括抗生素、抗真菌藥和抗病毒藥。此外,雌激素替代療法也被用于治療與絕經(jīng)相關(guān)的泌尿生殖系統(tǒng)癥狀。
- 妊娠并發(fā)癥包括妊娠期糖尿病、妊娠高血壓、子癇前期等,這些疾病對孕婦和胎兒的健康構(gòu)成重大風險。治療妊娠并發(fā)癥的藥物研發(fā)主要集中在控制血糖、血壓和改善胎兒生長等方面。
女性泌尿生殖器疾病和妊娠并發(fā)癥藥物靶點
- ALB
- ANGPT2
- AXL
- BAFF
- C5
- CA9
- CD19
- CD22
- CD247
- CD274
- CD276
- CD28
- CD38
- CD40
- CD40LG
- CD47
- CD70
- CD80
- CDH6
- CEACAM5
- CLDN6
- CSF2RA
- CSF3R
- CTAG1A
- CTLA4
- DNA2
- EGFR
- ENPP3
- EPCAM
- EPOR
- ERBB2
- ERBB3
- FCGR1A
- FCGRT
- FGFR3
- FOLR1
- FSHR
- GDF15
- GHR
- GLP1R
- GLP2R
- GNRHR
- IFNAR1
- Ifngr1
- IGF1R
- IL12A
- IL12RB1
- IL15RA
- IL17A
- IL18R1
- IL1B
- IL2
- IL2RA
- IL2RB
- IL2RG
- IL6
- INSR
- LAG3
- LHCGR
- LILRB2
- MASP2
- MET
- MS4A1
- MSLN
- MUC1
- MUC16
- NECTIN4
- NT5E
- PDCD1
- PSCA
- PTK7
- RHD
- SLC34A2
- SNAP25
- TACSTD2
- TGFB1
- TIGIT
- TNF
- TNFRSF10B
- TNFRSF17
- TNFRSF1A
- TNFRSF4
- TNFSF13
- TNFSF9
- TOP1
- TP53
- TPBG
- VEGFA
- VTCN1
- ZG16B
女性泌尿生殖器疾病和妊娠并發(fā)癥相關(guān)信號通路
Hippo信號通路在細胞增殖、分化、遷移和凋亡中起關(guān)鍵作用。研究表明,miR21通過干擾PP2A Bb調(diào)節(jié)Hippo信號通路,進而抑制滋養(yǎng)層細胞侵襲,與子癇前期(PE)的發(fā)病機制有關(guān) [1]。
異常的STAT信號傳導(dǎo)與妊娠疾病的發(fā)生有關(guān),包括反復(fù)著床失敗、先兆子癇、反復(fù)自然流產(chǎn)、早產(chǎn)和妊娠期糖尿病等 [2]。
Notch信號通路影響滋養(yǎng)細胞的分化、增殖、浸潤及遷移,參與胚胎著床、胎盤及其血管形成,與妊娠相關(guān)疾病的發(fā)生與發(fā)展有關(guān) [3]。
女性泌尿生殖器疾病和妊娠并發(fā)癥靶點相關(guān)產(chǎn)品推薦
● 靶點蛋白
CSB-MP619964HU1
Measured by its binding ability in a functional ELISA. Immobilized PD-1 at 2 μg/ml can bind Anti-PD-1 recombinant antibody, the EC50 of human PD-1 protein is 6.087-7.854 ng/ml.
CSB-MP878942HU1
Measured by its binding ability in a functional ELISA. Immobilized PD-L1 at 2 μg/ml can bind Anti- PD-L1 mouse monoclonal antibody (CSB-MA878942A1m, antigen from E.coli), the EC50 of human PD-L1 protein is 1.252-1.653 ng/mL
CSB-MP007763HU
Measured by its binding ability in a functional ELISA. Immobilized HER2 at 2 μg/ml can bind Trastuzumab, the EC50 is 2.179-2.825 ng/ml.
Human GH1 protein his/myc tag (CSB-MP009407HU) captured on COOH chip can bind Human GHR protein Fc tag (CSB-MP009411HU) with an affinity constant of 6.1 nM as detected by LSPR Assay.
CSB-MP011649HU3
Measured by its binding ability in a functional ELISA. Immobilized Human IL2RA at 2μg/mL can bind Anti-IL2RA recombinant antibody (CSB-RA011649MA1HU),the EC50 is 2.463-3.353 ng/mL.
CSB-MP006163HU1
Measured by its binding ability in a functional ELISA. Immobilized CD152 at 2 μg/ml can bind Anti-CD152 rabbit monoclonal antibody (CSB-RA213310A0HU), the EC50 of human CD152 protein is 27.14-34.82 ng/ml.
CSB-MP007479HU
Human EGF protein captured on COOH chip can bind Human EGFR protein, his and Myc tag (CSB-MP007479HU) with an affinity constant of 11.9nM as detected by LSPR Assay.
CSB-MP015044HUc9
Measured by its binding ability in a functional ELISA. Immobilized MSLN at 2 μg/ml can bind Anti-MSLN rabbit monoclonal antibody, the EC50 of the MSLN protein is 2.657-3.177 ng/ml.
● 穩(wěn)定細胞株
HEK293T/Human CLDN6 Stable Cell Line
CSB-SC007681HU
Untransfected HEK293T cells (green line) and transfected Human CLDN6 HEK293T stable cells (red line) were stained with anti-CLDN6/9 antibody (CSB-RA005508MA1HU) (2μg/1*106 cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.
HEK293T/Human ENPP3 Stable Cell Line
CSB-SC007681HU
Untransfected HEK293T cells (green line) and transfected Human ENPP3 HEK293T Stable cells (red line) were stained with anti-ENPP3 antibody (2μg/1*106 cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.
● 重組抗體
CSB-RA878942MA1HU
Overlay Peak curve showing Hela cells surface stained with CSB-RA878942MA1HU (red line) at 1:100.
CSB-RA244537A0HU
Overlay Peak curve showing Jurkat cells surface stained with CSB-RA244537A0HU (red line) at 1:50.
CSB-RA006163MA1HU
Overlay Peak curve showing JK cells surface stained with CSB-RA006163MA1HU (red line) at 1:50.
CSB-RA159341A0HU
Overlay histogram showing Jurkat cells stained with CSB-RA159341A0HU (red line) at 1:50.
產(chǎn)品名稱 | 貨號 | 靶點 | 反應(yīng)種屬 | 應(yīng)用范圍 |
---|---|---|---|---|
ALB Recombinant Monoclonal Antibody | CSB-RA264109A0HU | ALB | Human | ELISA, FC |
ANGPT2 Recombinant Monoclonal Antibody | CSB-RA191985A0HU | ANGPT2 | Human | ELISA, IHC |
ANGPT2 Recombinant Monoclonal Antibody | CSB-RA001707MA01HU | ANGPT2 | Human | ELISA |
C5 Recombinant Monoclonal Antibody | CSB-RA003995MA1HU | C5 | Human | ELISA, FC |
CA9 Recombinant Monoclonal Antibody | CSB-RA614990A0HU | CA9 | Human | ELISA, IHC |
CD19 Recombinant Monoclonal Antibody | CSB-RA004888A0HU | CD19 | Human | ELISA |
CD19 Recombinant Monoclonal Antibody | CSB-RA780821A0HU | CD19 | Human | ELISA, WB, IHC, IP |
CD19 Recombinant Monoclonal Antibody | CSB-RA004888MA1HU | CD19 | Human, Mouse | ELISA, WB |
CD22 Recombinant Monoclonal Antibody | CSB-RA962691A0HU | CD22 | Human | ELISA, IHC |
CD247 Recombinant Monoclonal Antibody | CSB-RA244537A0HU | CD247 | Human | ELISA, FC |
CD274 Recombinant Monoclonal Antibody | CSB-RA977797A0HU | CD274 | Human | ELISA, WB, IHC |
CD274 Recombinant Monoclonal Antibody | CSB-RA878942MA1HU | CD274 | Human | ELISA, IHC, FC |
CD38 Recombinant Monoclonal Antibody | CSB-RA796695A0HU | CD38 | Human | ELISA, WB, IHC |
CD40 Recombinant Monoclonal Antibody | CSB-RA004936MA1HU | CD40 | Human | ELISA, IF, FC |
CD47 Recombinant Monoclonal Antibody | CSB-RA802124A0HU | CD47 | Human | ELISA, WB, IHC, IF |
CD70 Recombinant Monoclonal Antibody | CSB-RA004954MA1HU | CD70 | Human | ELISA |
CD80 Recombinant Monoclonal Antibody | CSB-RA246383A0HU | CD80 | Human | ELISA, WB, IHC, IP |
CDH6 Recombinant Monoclonal Antibody | CSB-RA005055MA1HU | CDH6 | Human | ELISA |
CEACAM5 Recombinant Monoclonal Antibody | CSB-RA005165MA3HU | CEACAM5 | Human | ELISA, IF, FC |
CEACAM5 Recombinant Monoclonal Antibody | CSB-RA005165MA1HU | CEACAM5 | Human | ELISA |
● ELISA試劑盒
產(chǎn)品名稱 | 貨號 | 靶點 | 檢測范圍 | 靈敏度 |
---|---|---|---|---|
Bovine Albumin(Alb) ELISA kit | CSB-E08664b | ALB | 0.313 μg/mL-80 μg/mL | 0.148 μg/mL |
Mouse Albumin (Alb)ELISA Kit | CSB-E13878m | ALB | 0.781 μg/mL-200 μg/mL | 0.110 μg/mL |
Dog Albumin(Alb) ELISA Kit | CSB-E15757c | ALB | 0.273 μg/mL-35 μg/mL | 0.266 μg/mL |
Sheep Albumin (Alb)ELISA Kit | CSB-E15839Sh | ALB | 350 μg/mL-21.88 μg/mL | 5.5 μg/mL |
Horse Albumin(Alb) ELISA Kit | CSB-E16205Hs | ALB | 1.25 μg/mL-80 μg/mL | 1.247 μg/mL |
Pig Albumin (Alb) ELISA Kit | CSB-E16207p | ALB | 0.03 μg/mL-7000 μg/mL | 0.03 μg/mL |
Goat Albumin (Alb)ELISA Kit | CSB-E15758G | ALB | 0.17 μg/mL-350 μg/mL | 0.17 μg/mL |
Guinea Pig Albumin(Alb) ELISA kit | CSB-E15765Gp | ALB | 0.156 μg/mL-10 μg/mL | 0.09 μg/mL |
Rabbit Albumin(Alb) ELISA Kit | CSB-E16204Rb | ALB | 0.273 μg/mL-70 μg/mL | 0.117 μg/mL |
Human Angiopoietin 2,ANG-2 ELISA Kit | CSB-E04500h | ANGPT2 | 39 pg/mL-2500 pg/mL | 9.75 pg/mL |
Rat Angiopoietin 2,ANG-2 ELISA Kit | CSB-E07304r | ANGPT2 | Request Information | Request Information |
Mouse Angiopoietin 2,ANG-2 ELISA Kit | CSB-E07305m | ANGPT2 | 0.156 pg/mL-10 pg/mL | 0.039 pg/mL |
Pig Angiopoietin 2,ANG-2 ELISA Kit | CSB-E08460p | ANGPT2 | 0.94 ng/mL-60 ng/mL | 0.235 ng/mL |
Human Tyrosine-protein kinase receptor UFO (AXL) ELISA Kit | CSB-EL002476HU | AXL | 31.25 pg/mL-2000 pg/mL | 7.81 pg/mL |
Mouse Tyrosine-protein kinase receptor UFO(AXL) ELISA Kit | CSB-EL002476MO | AXL | 31.25 pg/ml-2000 pg/ml | 7.81 pg/ml |
Mouse Complement 5,C5 ELISA Kit | CSB-E13802m | C5 | 0.25 ng/mL-16 ng/mL | 0.06 ng/mL |
Rat Complement fragment 5,C5 ELISA Kit | CSB-E14363r | C5 | 9.38 ng/mL-600 ng/mL | 2.34 ng/mL |
Monkey complement C5 (C5) ELISA kit | CSB-EL003995MK | C5 | 0.625 ng/mL-40 ng/mL | 0.156 ng/mL |
Human Carbonic Anhydrase 9(CA9) ELISA Kit | CSB-E13266h | CA9 | 31.25 pg/mL-2000 pg/mL | 7.81 pg/mL |
Human T-cell surface glycoprotein CD3 zeta chain (CD247) ELISA kit | CSB-EL004904HU | CD247 | 0.156 ng/mL-10 ng/mL | 0.039 ng/mL |
藥物研發(fā)解決方案
特色服務(wù)項目
專家講堂
參考文獻:
[1] MiR21 modulates the Hippo signaling pathway via interference with PP2A Bb to inhibit trophoblast invasion and cause preeclampsia [J].Molecular Therapy: Nucleic Acids, 2022.
[2] Research progress on the STAT signaling pathway in pregnancy and pregnancy-associated disorders [J].Front Immunol,2023.
[3] Notch signalling in placental development and gestational diseases [J].Placenta,2017.